Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
University of Utah · Huntsman Cancer Institute · +25 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
487
total citations
- FWCI
- 117.45
- Percentile
- 100%
- References
- 31
Citations per year
Authors
21- NANeeraj AgarwalCorresponding
University of Utah, Huntsman Cancer Institute
- AAArun Azad
Peter MacCallum Cancer Centre
- JCJoan Carles
Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology
- APAndré P. Fay
Pontifícia Universidade Católica do Rio Grande do Sul
- NMNobuaki Matsubara
National Cancer Center Hospital East
Topics & keywords
Topics
Keywords
- Enzalutamide
- Medicine
- Prostate cancer
- Placebo
- Internal medicine
- Clinical endpoint
- Oncology
- Population
No related works found for this paper.